The High-Resolution Melting Analysis Market size in the Asia Pacific was valued at USD 58.47 million in 2022. It is further projected to be growing at a CAGR of 5.2% and worth USD 75.34 million by 2027.
Due to developing applications in epigenetics, more significant R&D funding, and digitalization of mutations, high-resolution melting analysis is becoming increasingly popular. HRM analysis has several benefits, including the elimination of probes, the use of a closed-tube system, the prevention of contamination post-PCR, and the ability to analyze melting profiles with high precision. Due to numerous prominent businesses are doing research and development in this industry, the APAC high-resolution melting analysis market is predicted to grow effectively. In addition, the U.S. Food and Drug Administration has authorized several therapies customized to a patient's genomic profile or the genetic makeup of their tumor.
Factors such as rising chronic illness prevalence, increasing desire for personalized medication and supporting government efforts are projected to boost the HRM analysis market in the APAC region majorly. Precision medicine is a healthy and creative way of preventing and treating diseases that consider a patient's genetic composition, lifestyle, and environment. Precision medicine is gaining traction in the new era of next-generation sequencing (NGS), genomics, and big data analysis. Furthermore, the FDA has already addressed several therapies to address specific aspects of a patient's tumor, such as genetic composition or genomic profile. As a result, HRM analysis is expected to expand in the following years. Growth potential in biotechnology research, well-established reimbursement procedures, and growing government funding in academic institutions are all factors to consider. A favorable regulatory framework is also vital for the growth of the educational research sector. Furthermore, the OECD reports that due to the importance of intellectual property, the number of patents awarded in biotechnology has increased significantly. Therefore, the need for human resource management products in the academic research segment is predicted to rise as molecular biology, biotechnology, and medical advances.
However, technological barriers associated with HRM-QPCR analysis are expected to limit the market's growth. The APAC HRM testing market is under severe threat from Data storage concerns, decreased prices for other genotyping technologies, and expected reductions in alternative genotyping methods contributing to the market's growth. Another significant issue is the security concerns around data storage.
This research report on Asia Pacific High-Resolution Melting Analysis Market has been segmented and sub-segmented into the following categories.
By Product and Service:
By End User:
Due to exponentially higher population numbers, Asia-Pacific is expected to expand at the fastest CAGR throughout the forecast period. Y-O-Y growth in the population, a growing incidence of malignancies, and other chronic illnesses are the primary contributors, resulting in enormous unmet medical requirements. The APAC high-resolution melting analysis market is primarily boosted by extensive epigenetics research and development and the widespread application of this technique in mutation scanning and epigenetics. Aside from that, the high-resolution melting analysis market is being boosted by increased demand for customized treatment, the rising prevalence of chronic illnesses, and favorable government reforms for innovative therapeutics. Personalized medicine is a new way of developing new diagnoses and treatments. Different genetic combinations, environmental circumstances, and lifestyle factors all benefit from personalized therapy. Recent advancements in genomics, next-generation sequencing, and big data analytics have fuelled demand for customized treatment, fuelling the high-resolution melting analysis market in the Asia Pacific.
KEY MARKE PLAYERS:
Companies playing a leading role in the Asia Pacific high-resolution melting analysis market are Thermo Fisher Scientific Inc. (U.S.), F. Hofmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories (U.S.), and QIAGEN N.V. (Netherlands). Other players in the market include Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Illumina, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Novacyt (France), Azura Genomics (U.S.), Canon Biomedical (U.S.), and PREMIER Biosoft (U.S.), among others.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]